Showing results (151-160 of 305) with videos related to
Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapyMarco Ladetto, Daniela Drandi, Mara Compagno, et al.Clinical Lymphoma|July 13, 2004
A large-scale study of bone marrow involvement in patients with Hodgkin's lymphomaAlessandro Levis, Daniela Pietrasanta, Laura Godio, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2007
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma NetworkAntonio Palumbo, Patrizia Falco, Paolo Corradini, et al.Blood|May 29, 2008
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trialAntonio Palumbo, Sara Bringhen, Anna M Liberati, et al.European Journal of Haematology|March 3, 2007
Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myelomaBenedetto Bruno, Roberto Sorasio, Francesca Patriarca, et al.The New England Journal of Medicine|March 16, 2007
A comparison of allografting with autografting for newly diagnosed myelomaBenedetto Bruno, Marcello Rotta, Francesca Patriarca, et al.Haematologica|April 26, 2014
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapyMaría-Victoria Mateos, Sara Bringhen, Paul G Richardson, et al.Haematologica|February 9, 2019
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studiesSara Bringhen, Roberto Mina, Maria Teresa Petrucci, et al.Cancer|June 28, 2021
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma NetworkFrancesca Gay, Andreas Günther, Massimo Offidani, et al.Hemasphere|October 7, 2022
Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple MyelomaPieter Sonneveld, Sonja Zweegman, Michele Cavo, et al.Pageof 31